Bridgewater Associates’s Adient ADNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.96M Buy
378,873
+88,774
+31% +$1.9M 0.03% 407
2026
Q1
$5.86M Sell
290,099
-139,181
-32% -$3.1M 0.03% 385
2025
Q4
$8.23M Sell
429,280
-3,163
-0.7% -$66.5K 0.03% 403
2025
Q3
$10.4M Buy
+432,443
New +$10.1M 0.04% 327
2022
Q3
– Sell
-66,124
Closed -$1.96M – 869
2022
Q2
$1.96M Sell
66,124
-2,272
-3% -$76.3K 0.01% 688
2022
Q1
$2.79M Sell
68,396
-17,214
-20% -$739K 0.01% 612
2021
Q4
$4.1M Sell
85,610
-56,958
-40% -$2.55M 0.02% 338
2021
Q3
$5.91M Buy
142,568
+50,766
+55% +$2.02M 0.03% 270
2021
Q2
$4.15M Sell
91,802
-6,894
-7% -$322K 0.03% 363
2021
Q1
$4.36M Buy
+98,696
New +$3.73M 0.04% 231
2020
Q4
– Sell
-24,934
Closed -$432K – 527
2020
Q3
$432K Buy
24,934
+4,695
+23% +$81.8K 0.01% 411
2020
Q2
$332K Sell
20,239
-1,378
-6% -$21K 0.01% 316
2020
Q1
$196K Sell
21,617
-10,386
-32% -$209K ﹤0.01% 381
2019
Q4
$680K Buy
+32,003
New +$710K 0.01% 379

Other funds holding ADNT

Bridgewater Associates's ADNT Position: Q2 2026 in Review

Bridgewater Associates increased its Adient (ADNT) stake by 31% in Q2 2026, buying an estimated $1.9M and bringing the position to 378,873 shares worth $6.96M. The position accounts for 0.03% of the portfolio, ranked #407.

Bridgewater Associates first reported a position in ADNT in Q4 2019 and has held it in 14 quarters since. The position peaked at $10.4M in Q3 2025. 313 funds tracked by Wall St. Rank hold ADNT as of Q2 2026.

  • Bridgewater Associates held 378,873 shares of Adient worth $6.96M as of Q2 2026.
  • Bridgewater Associates bought 88,774 Adient shares in Q2 2026, an estimated $1.9M.
  • Adient made up 0.03% of Bridgewater Associates's portfolio in Q2 2026, its #407 holding.
  • Bridgewater Associates first reported a position in Adient in Q4 2019 and has held it in 14 quarters since.
  • Bridgewater Associates's Adient position peaked at $10.4M in Q3 2025.
  • 313 funds tracked by Wall St. Rank held Adient as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.